Novo Nordisk Faces Unprecedented Price Pressures, Shares Plunge

Novo Nordisk, a Danish obesity drug giant, experienced a sharp drop in shares, with a 20% decline after warning of 'unprecedented' pricing pressures in 2026. The company predicts profits and sales may fall by up to 13% this year, primarily due to intense competition and U.S. policy changes.

Novo Nordisk, the Danish pharmaceutical heavyweight renowned for its obesity treatments, faced a hefty 20% drop in shares following an alarming announcement about potential pricing pressures in 2026. As fierce competition looms, the company's ominous forecast has instilled uncertainty in market analysts.

The CEO, Mike Doustdar, disclosed that 'unprecedented pricing pressure' is reflected in this year's guidance, causing distress to shareholders. The president's push to slash drug costs, coupled with increased demands from insurers, are cited as primary catalysts behind the predicted plunge in profits and sales.

Additionally, Novo is grappling with significant challenges from emerging companies entering the obesity drug market. This competitive landscape, coupled with patent expiries and copycat threats, further compounds the pressure, yet the rise in oral drug sales offers a glimmer of hope amidst the turbulent period.

(With inputs from agencies.)